Europe Alzheimers Therapeutics Market Size & Outlook
Europe alzheimers therapeutics market, 2018-2030 (US$M)
Related Markets
Europe alzheimers therapeutics market highlights
- The Europe alzheimers therapeutics market generated a revenue of USD 1,152.9 million in 2022.
- The market is expected to grow at a CAGR of 18.6% from 2023 to 2030.
- In terms of segment, cholinesterase inhibitors was the largest revenue generating drug class in 2022.
- Combination Drugs is the most lucrative drug class segment registering the fastest growth during the forecast period.
- Country-wise, Spain is expected to register the highest CAGR from 2023 to 2030.
Europe data book summary
| Market revenue in 2022 | USD 1,152.9 million |
| Market revenue in 2030 | USD 4,505.2 million |
| Growth rate | 18.6% (CAGR from 2022 to 2030) |
| Largest segment | Cholinesterase inhibitors |
| Fastest growing segment | Combination Drugs |
| Historical data covered | 2018 - 2021 |
| Base year for estimation | 2022 |
| Forecast period covered | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Cholinesterase inhibitors, NMDA Receptor Antagonist, Combination Drugs |
| Key market players worldwide | Eisai Co Ltd, Novartis AG ADR, AbbVie Inc, H. Lundbeck AS Class A, Biogen Inc, Roche Holding AG ADR, Daiichi Sankyo Co Ltd, Johnson & Johnson, AC Immune SA |
Other key industry trends
- In terms of revenue, Europe region accounted for 27.4% of the global alzheimers therapeutics market in 2022.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- North America is the fastest growing regional market and is projected to reach USD 6,823.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Alzheimers Therapeutics Market Scope
Alzheimers Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe alzheimers therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to alzheimers therapeutics market will help companies and investors design strategic landscapes.
Cholinesterase inhibitors was the largest segment with a revenue share of 52.29% in 2022. Horizon Databook has segmented the Europe alzheimers therapeutics market based on cholinesterase inhibitors, nmda receptor antagonist, combination drugs covering the revenue growth of each sub-segment from 2018 to 2030.
Europe is the second-largest market for Alzheimer's treatment drugs. It is expected to grow at a significant pace over the forecast period owing to the region's high prevalence rate of AD. Government initiatives and awareness programs are expected to stimulate growth of Alzheimer's therapeutics market in the European region.
European Commission (EC) has launched several projects in the diagnostic & therapeutic fields of AD. These projects include European Collaboration on Dementia (EUROCODE) Project; Alzheimer Cooperative Valuation in Europe (ALCOVE), which was a joint action; and initiatives related to Alzheimer's & other dementias in the EC.
Moreover, the European Union has adopted a policy framework to help people living with dementia by improving care policies and practices to enhance the lives of patients with Alzheimer's & other dementia.
Reasons to subscribe to Europe alzheimers therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe alzheimers therapeutics market databook
-
Our clientele includes a mix of alzheimers therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe alzheimers therapeutics market , including forecasts for subscribers. This continent databook contains high-level insights into Europe alzheimers therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Europe alzheimers therapeutics market size, by country, 2018-2030 (US$M)
Europe Alzheimers Therapeutics Market Outlook Share, 2022 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
